AstraZeneca to streamline US commercial business

Wilmington, DE - AstraZeneca (NYSE:AZN) announced today that it will streamline portions of its U.S. commercial business as part of the company's strategy to operate its business more effectively and efficiently to best serve patients in the United States. The changes will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generic medicines.

As part of the transformation, AstraZeneca will identify more efficient ways of working throughout its U.S. business and reduce its cost base - including the reduction of approximately 400 positions at the company's Wilmington headquarters and some field-based, non-sales roles.

About 70 of the estimated 400 roles will come from existing vacancies. In addition, employees will have the option to self-identify to potentially leave the company. All decisions will be finalized by early December.

"This will be very difficult for our entire organization, particularly the people who are directly impacted," said Rich Fante, President, AstraZeneca U.S. & CEO, North America. "However, these changes are necessary to build a leaner, more efficient organization that will enable the company to continue delivering against our mission of patient health and sustaining a strong business for years to come."

NOTES TO EDITORS:

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&MeTM Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.